Alzamend neuro, inc.ALZN.US Overview
ALZN Overall Performance
ALZN AI Analysis & Strategy
ALZN Recent Performance
5.33%
Alzamend neuro, inc.
0.81%
Avg of Sector
-1.14%
S&P500
ALZN PowerScanner
ALZN Key Information
ALZN Valuation Metrics
ALZN Earnings Table
ALZN Profile
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.